JP2020534374A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534374A5 JP2020534374A5 JP2020538752A JP2020538752A JP2020534374A5 JP 2020534374 A5 JP2020534374 A5 JP 2020534374A5 JP 2020538752 A JP2020538752 A JP 2020538752A JP 2020538752 A JP2020538752 A JP 2020538752A JP 2020534374 A5 JP2020534374 A5 JP 2020534374A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- amino
- compound
- alaninate
- phosphoryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 4-amino-2-oxopyrimidine-1 (2H) -yl Chemical group 0.000 claims 84
- 150000001875 compounds Chemical class 0.000 claims 46
- 239000000203 mixture Substances 0.000 claims 42
- 125000000217 alkyl group Chemical group 0.000 claims 40
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 24
- 125000001188 haloalkyl group Chemical group 0.000 claims 20
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000000847 cytosin-1-yl group Chemical group [*]N1C(=O)N=C(N([H])[H])C([H])=C1[H] 0.000 claims 8
- 125000001475 halogen functional group Chemical group 0.000 claims 8
- 125000001624 naphthyl group Chemical group 0.000 claims 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 6
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 claims 4
- VOWPVJACXJNHBC-UHFFFAOYSA-N methyl diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(OC)OC1=CC=CC=C1 VOWPVJACXJNHBC-UHFFFAOYSA-N 0.000 claims 4
- 229940122604 HCV protease inhibitor Drugs 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 101800000440 Non-structural protein NS3A Proteins 0.000 claims 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- FKRSSPOQAMALKA-CUPIEXAXSA-N daclatasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C=2C=CC(=CC=2)C=2N=C(NC=2)[C@H]2N(CCC2)C(=O)[C@@H](NC(=O)OC)C(C)C)=CN1 FKRSSPOQAMALKA-CUPIEXAXSA-N 0.000 claims 1
- 229960005449 daclatasvir Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 0 C[C@@]1[C@](N(C=CC(N)=N2)C2=O)O[C@](*)(COP(*)(*)=*)[C@@]1O Chemical compound C[C@@]1[C@](N(C=CC(N)=N2)C2=O)O[C@](*)(COP(*)(*)=*)[C@@]1O 0.000 description 17
- KTXAFRDFKKNLLB-UKZBMLMBSA-N C[C@@H](C(OC1CCCCC1)=N)/N=C\[P@](OC[C@](C[C@@H]1C)(O[C@H]1N(C=CC(N)=N1)C1=O)F)(Oc1ccccc1)=O Chemical compound C[C@@H](C(OC1CCCCC1)=N)/N=C\[P@](OC[C@](C[C@@H]1C)(O[C@H]1N(C=CC(N)=N1)C1=O)F)(Oc1ccccc1)=O KTXAFRDFKKNLLB-UKZBMLMBSA-N 0.000 description 3
- CNMZIOBNQMYSPI-XWFOKKAGSA-N CC(C)OC([C@H](C)/N=C\[P@](OC[C@](C[C@@H]1C)([O-2][C@H]1N(C=CC(N)=N1)C1=O)F)(Oc1ccccc1)=O)=N Chemical compound CC(C)OC([C@H](C)/N=C\[P@](OC[C@](C[C@@H]1C)([O-2][C@H]1N(C=CC(N)=N1)C1=O)F)(Oc1ccccc1)=O)=N CNMZIOBNQMYSPI-XWFOKKAGSA-N 0.000 description 2
- QDQVXVRZVCTVHE-YFKPBYRVSA-N CC(C)OC([C@H](C)N)=O Chemical compound CC(C)OC([C@H](C)N)=O QDQVXVRZVCTVHE-YFKPBYRVSA-N 0.000 description 2
- DYLSZPQUPRDHPC-IIEDWPIASA-N CC(C)OC([C@H](C)N[P@@](Oc1ccccc1)([U]C[C@](C[C@@H]1C)(O[C@H]1N(C=CC(N1)=O)C1=O)F)=O)=O Chemical compound CC(C)OC([C@H](C)N[P@@](Oc1ccccc1)([U]C[C@](C[C@@H]1C)(O[C@H]1N(C=CC(N1)=O)C1=O)F)=O)=O DYLSZPQUPRDHPC-IIEDWPIASA-N 0.000 description 2
- JKNSNVFEMWTSSL-OGTHKYEHSA-N CC(C)OC([C@H](C)/N=C/[P@](OCC(C[C@@H]1C)O[C@H]1N(C=CC(N1)=O)C1=O)(Oc1ccccc1)=O)=O Chemical compound CC(C)OC([C@H](C)/N=C/[P@](OCC(C[C@@H]1C)O[C@H]1N(C=CC(N1)=O)C1=O)(Oc1ccccc1)=O)=O JKNSNVFEMWTSSL-OGTHKYEHSA-N 0.000 description 1
- OTXDPFGLPIQLGO-RIEPGIFKSA-N CC(C)OC([C@H](C)/N=C\[P@](OC[C@](C[C@@H]1C)([O-2][C@H]1N(C=CC(N)=N1)C1=O)F)(Oc1cccc2ccccc12)=O)=N Chemical compound CC(C)OC([C@H](C)/N=C\[P@](OC[C@](C[C@@H]1C)([O-2][C@H]1N(C=CC(N)=N1)C1=O)F)(Oc1cccc2ccccc12)=O)=N OTXDPFGLPIQLGO-RIEPGIFKSA-N 0.000 description 1
- SGRMHUQFYMFOQM-LRQOYWODSA-N CC(C)OC([C@H](C)/N=C\[P@](OC[C@](C[C@@H]1C)([O-2][C@H]1N(C=CC(N)=N1)C1=O)F)(Oc1ccccc1)=O)=O Chemical compound CC(C)OC([C@H](C)/N=C\[P@](OC[C@](C[C@@H]1C)([O-2][C@H]1N(C=CC(N)=N1)C1=O)F)(Oc1ccccc1)=O)=O SGRMHUQFYMFOQM-LRQOYWODSA-N 0.000 description 1
- PJRSPBLUQVTYAQ-RGMNGODLSA-N CC(C)OC([C@H](C)N)=[U] Chemical compound CC(C)OC([C@H](C)N)=[U] PJRSPBLUQVTYAQ-RGMNGODLSA-N 0.000 description 1
- VJHHGWFJYRMRNH-LURJTMIESA-N CC(C)OC([C@H](C)N=C)=O Chemical compound CC(C)OC([C@H](C)N=C)=O VJHHGWFJYRMRNH-LURJTMIESA-N 0.000 description 1
- QCUHYVKRXXSMQE-WZJZPTLQSA-N CC(C)OC([C@H](C)N[P@](OCC(C[C@@H]1C)[U][C@H]1N(C=CC(NC)=N1)C1=O)(Oc1ccccc1)=O)=O Chemical compound CC(C)OC([C@H](C)N[P@](OCC(C[C@@H]1C)[U][C@H]1N(C=CC(NC)=N1)C1=O)(Oc1ccccc1)=O)=O QCUHYVKRXXSMQE-WZJZPTLQSA-N 0.000 description 1
- LDCPPPWYJMJKIX-UHFFFAOYSA-N CC(C1)C(N(C=CC(N)=N2)C2=O)OC1(COP(Oc1ccccc1)=O)F Chemical compound CC(C1)C(N(C=CC(N)=N2)C2=O)OC1(COP(Oc1ccccc1)=O)F LDCPPPWYJMJKIX-UHFFFAOYSA-N 0.000 description 1
- HAJXAUQYFJBWOD-UHFFFAOYSA-N CC(C1O)(C(N(C=CC(N)=N2)C2=O)OC1(COP(Oc1ccccc1)=O)F)F Chemical compound CC(C1O)(C(N(C=CC(N)=N2)C2=O)OC1(COP(Oc1ccccc1)=O)F)F HAJXAUQYFJBWOD-UHFFFAOYSA-N 0.000 description 1
- GIPKUCBOGCOBQN-UHFFFAOYSA-N CC1(C(N(C=CC(N2)=O)C2=O)OC(COP(Oc2ccccc2)=O)C1O)F Chemical compound CC1(C(N(C=CC(N2)=O)C2=O)OC(COP(Oc2ccccc2)=O)C1O)F GIPKUCBOGCOBQN-UHFFFAOYSA-N 0.000 description 1
- AKEYUWUEAXIBTF-UHFFFAOYSA-N CNc1c(cccc2)c2ccc1 Chemical compound CNc1c(cccc2)c2ccc1 AKEYUWUEAXIBTF-UHFFFAOYSA-N 0.000 description 1
- AFBPFSWMIHJQDM-UHFFFAOYSA-N CNc1ccccc1 Chemical compound CNc1ccccc1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
- LKIBFKFRKYOEMC-WRKKGLQKSA-N C[C@@H](C(OC1CCCCC1)=O)NP(N[C@@H](C)C(OC1CCCCC1)=O)(OC[C@](C[C@@H]1C)([O-2][C@H]1N(C=CC(N)=N1)C1=O)F)=[U] Chemical compound C[C@@H](C(OC1CCCCC1)=O)NP(N[C@@H](C)C(OC1CCCCC1)=O)(OC[C@](C[C@@H]1C)([O-2][C@H]1N(C=CC(N)=N1)C1=O)F)=[U] LKIBFKFRKYOEMC-WRKKGLQKSA-N 0.000 description 1
- JWNOXSHZFLRHFH-CORIIIEPSA-O C[C@@H]1[C@H](N(C=CC(N2)=O)C2=O)O[C@H](CO[P+](Oc2ccccc2)=O)C1 Chemical compound C[C@@H]1[C@H](N(C=CC(N2)=O)C2=O)O[C@H](CO[P+](Oc2ccccc2)=O)C1 JWNOXSHZFLRHFH-CORIIIEPSA-O 0.000 description 1
- UUFYWTLYUGRALJ-DUVNUKRYSA-O C[C@@H]1[C@H](N(C=CC(NC)=N2)C2=O)O[C@H](CO[P+](Oc2ccccc2)=O)C1 Chemical compound C[C@@H]1[C@H](N(C=CC(NC)=N2)C2=O)O[C@H](CO[P+](Oc2ccccc2)=O)C1 UUFYWTLYUGRALJ-DUVNUKRYSA-O 0.000 description 1
- AFBBDSOIWBNYLL-DQYAHDQKSA-N C[C@H](CN(C)P(N[C@@H](C)C(OC1CCCCC1)=O)(OC[C@](C[C@@H]1C)(O[C@H]1N(/C=C\C(C)=C)C(C)=O)F)=O)C(OC1CCCCC1)=O Chemical compound C[C@H](CN(C)P(N[C@@H](C)C(OC1CCCCC1)=O)(OC[C@](C[C@@H]1C)(O[C@H]1N(/C=C\C(C)=C)C(C)=O)F)=O)C(OC1CCCCC1)=O AFBBDSOIWBNYLL-DQYAHDQKSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561237P | 2017-09-21 | 2017-09-21 | |
| US62/561,237 | 2017-09-21 | ||
| PCT/US2018/052239 WO2019060740A1 (en) | 2017-09-21 | 2018-09-21 | 4'-FLUORO-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534374A JP2020534374A (ja) | 2020-11-26 |
| JP2020534374A5 true JP2020534374A5 (enExample) | 2021-11-04 |
| JP7299897B2 JP7299897B2 (ja) | 2023-06-28 |
Family
ID=65810030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020538752A Active JP7299897B2 (ja) | 2017-09-21 | 2018-09-21 | Ｈｃｖのｒｎａ複製阻害剤としての４’－フルオロ－２’－メチル置換ヌクレオシド誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10682369B2 (enExample) |
| EP (1) | EP3684374B1 (enExample) |
| JP (1) | JP7299897B2 (enExample) |
| KR (1) | KR102735678B1 (enExample) |
| CN (1) | CN111194217B (enExample) |
| AR (1) | AR112702A1 (enExample) |
| AU (1) | AU2018335411B2 (enExample) |
| CA (1) | CA3075645A1 (enExample) |
| IL (1) | IL273398B2 (enExample) |
| SG (1) | SG11202002431SA (enExample) |
| TW (1) | TWI860279B (enExample) |
| WO (1) | WO2019060740A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180200280A1 (en) * | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
| TWI860279B (zh) | 2017-09-21 | 2024-11-01 | 美商里伯賽恩斯有限責任公司 | 作為hcv rna複製抑制劑之經4'-氟-2'-甲基取代之核苷衍生物 |
| EP3865535A1 (en) | 2020-02-11 | 2021-08-18 | Bosti Trading Ltd. | New method of synthesis of chitosan derivatives and uses thereof |
| TW202144465A (zh) | 2020-02-11 | 2021-12-01 | 瑞士商諾和席卓股份有限公司 | 合成聚葡萄胺糖衍生物之新方法及其用途 |
| WO2022174179A1 (en) * | 2021-02-15 | 2022-08-18 | Emory University | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| AR126678A1 (es) | 2021-08-06 | 2023-11-01 | Novochizol Sa | Composiciones para el cuidado de las plantas y usos de las mismas |
| CN117835822A (zh) | 2021-08-06 | 2024-04-05 | 诺和席卓股份有限公司 | 包含可溶性交联壳聚糖的复合凝胶、聚合物支架、聚集体和薄膜的制备及其用途 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU498131B2 (en) | 1974-02-26 | 1979-02-15 | Ciba-Geigy Ag | Production of cephems by cyclization |
| US4147864A (en) | 1975-02-20 | 1979-04-03 | Ciba-Geigy Corporation | Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds |
| US4322347A (en) | 1978-04-03 | 1982-03-30 | Bristol-Myers Company | 2-Carbamoyloxymethyl-penicillin derivatives |
| WO1986006380A1 (fr) | 1985-04-30 | 1986-11-06 | Takeda Chemical Industries, Ltd. | Composes antibacteriens, utilisation et preparation |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| AU723730B2 (en) | 1996-04-23 | 2000-09-07 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of IMPDH enzyme |
| IN183120B (enExample) | 1996-10-18 | 1999-09-11 | Vertex Pharma | |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| DE69816280T2 (de) | 1997-03-14 | 2004-05-27 | Vertex Pharmaceuticals Inc., Cambridge | Inhibitoren des impdh-enzyms |
| US6010848A (en) | 1997-07-02 | 2000-01-04 | Smithkline Beecham Corporation | Screening methods using an atpase protein from hepatitis C virus |
| PT1012180E (pt) | 1997-08-11 | 2005-04-29 | Boehringer Ingelheim Ca Ltd | Analogos de peptidos inibidores da hepatite c |
| CA2338490A1 (en) | 1998-07-27 | 2000-02-10 | Sergio Altamura | Diketoacid-derivatives as inhibitors of polymerases |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| KR20010099623A (ko) | 1998-08-21 | 2001-11-09 | 비로파마 인코포레이티드 | 바이러스 감염 및 관련 질병을 치료 또는 예방하는화합물, 조성물 및 방법 |
| US6440985B1 (en) | 1998-09-04 | 2002-08-27 | Viropharma Incorporated | Methods for treating viral infections |
| AU751457B2 (en) | 1998-09-25 | 2002-08-15 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
| EE200100492A (et) | 1999-03-19 | 2002-12-16 | Vertex Pharmaceuticals Incorporated | Ensüümi IMPDH inhibiitorid |
| CA2389745C (en) | 1999-11-04 | 2010-03-23 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| US20040034041A1 (en) | 2000-05-10 | 2004-02-19 | Dashyant Dhanak | Novel anti-infectives |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| US20030170891A1 (en) | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| JP2005500287A (ja) | 2001-06-11 | 2005-01-06 | シャイアー バイオケム インコーポレイテッド | Ｆｌａｖｉｖｉｒｕｓ感染の処置または予防のための化合物および方法 |
| PT1401825E (pt) | 2001-06-11 | 2009-10-23 | Virochem Pharma Inc | Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| JP4558314B2 (ja) | 2001-07-20 | 2010-10-06 | ベーリンガー インゲルハイム （カナダ） リミテッド | ウイルスポリメラーゼインヒビター |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| JP2005511573A (ja) | 2001-11-02 | 2005-04-28 | グラクソ グループ リミテッド | Ｈｃｖ阻害剤としての４−（５−員）−ヘテロアリールアシルピロリジン誘導体 |
| JP2005515172A (ja) | 2001-11-02 | 2005-05-26 | グラクソ グループ リミテッド | Ｈｃｖ阻害剤としての４−（６−員）−ヘテロアリールアシルピロリジン誘導体 |
| US20050009873A1 (en) | 2001-11-02 | 2005-01-13 | Gianpaolo Bravi | Acyl dihydro pyrrole derivatives as hcv inhibitors |
| AU2003269890A1 (en) | 2002-06-21 | 2004-01-06 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| CN101172992A (zh) * | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 用于治疗黄病毒感染的修饰的2′和3′－核苷前药 |
| MXPA05008736A (es) * | 2003-02-19 | 2005-10-05 | Univ Yale | Analogos de nucleosido antivirales y metodos para tratar infecciones virales, especialmente infecciones por vih. |
| US20050020884A1 (en) | 2003-02-25 | 2005-01-27 | Hart Charles C. | Surgical access system |
| BRPI0409680A (pt) | 2003-04-25 | 2006-04-18 | Gilead Sciences Inc | análogos de fosfonato anti-cáncer |
| AU2004235848B2 (en) | 2003-05-09 | 2011-08-04 | Boehringer Ingelheim International Gmbh | Hepatitis C virus NS5B polymerase inhibitor binding pocket |
| WO2005020884A2 (en) | 2003-05-14 | 2005-03-10 | Idenix (Cayman) Limited | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
| KR100883703B1 (ko) | 2003-05-30 | 2009-02-12 | 파마셋 인코포레이티드 | 변형 불소화 뉴클레오시드 유사체 |
| US7507859B2 (en) | 2003-06-16 | 2009-03-24 | Fifth Base Llc | Functional synthetic molecules and macromolecules for gene delivery |
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| UA84050C2 (en) | 2004-01-30 | 2008-09-10 | Медивир Аб | Hcv ns-3-serine protease inhibitors |
| JP2008523098A (ja) | 2004-12-10 | 2008-07-03 | エモリー・ユニバーシテイ | ウィルス感染および異常細胞増殖の治療用の２′および３′−置換シクロブチルヌクレオシド類縁体 |
| CN101287472B (zh) * | 2005-08-15 | 2011-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物 |
| CN101384609A (zh) * | 2006-02-14 | 2009-03-11 | 默克公司 | 用于治疗rna依赖性rna病毒感染的氨基磷酸（核苷）（芳基）酯 |
| WO2007095269A2 (en) | 2006-02-14 | 2007-08-23 | Merck & Co., Inc. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| GB2442001A (en) | 2006-08-11 | 2008-03-26 | Chembiotech | Nanoparticle - i-motif nucleic acid bioconjugates |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2673649A1 (en) | 2007-01-05 | 2008-07-17 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| GB0709791D0 (en) | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
| US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US8716263B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| US20110150836A1 (en) * | 2009-12-22 | 2011-06-23 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| PH12013500033A1 (en) | 2010-07-19 | 2017-07-26 | Gilead Sciences Inc | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| SG188497A1 (en) | 2010-09-22 | 2013-05-31 | Alios Biopharma Inc | Substituted nucleotide analogs |
| RU2640582C2 (ru) | 2011-08-01 | 2018-01-10 | Мбс Фарма, Инк. | Производные витамина в6 нуклеотидов, ациклических нуклеотидов и ациклических нуклеозидных фосфонатов |
| EP2709613B2 (en) * | 2011-09-16 | 2020-08-12 | Gilead Pharmasset LLC | Methods for treating hcv |
| PL2794629T3 (pl) * | 2011-12-20 | 2018-02-28 | Riboscience Llc | 2',4'-difluoro-2'-metylo-podstawione pochodne nukleozydowe jako inhibitory replikacji rna hcv |
| WO2013142159A1 (en) * | 2012-03-21 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| ES2865402T3 (es) * | 2012-12-21 | 2021-10-15 | Janssen Biopharma Inc | 4'-fluoronucleósidos, 4'-fluoronucleótidos y análogos de los mismos para el tratamiento del VHC |
| US9233974B2 (en) * | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| CN110156838A (zh) * | 2013-05-14 | 2019-08-23 | 北京美倍他药物研究有限公司 | 磷酸/膦酸衍生物及其医药用途 |
| NZ714927A (en) * | 2013-05-16 | 2020-09-25 | Riboscience Llc | 4’-fluoro-2’-methyl substituted nucleoside derivatives |
| US20180200280A1 (en) * | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
| JP2016519146A (ja) * | 2013-05-16 | 2016-06-30 | リボサイエンス・エルエルシー | ４’−アジド，３’−デオキシ−３’−フルオロ置換ヌクレオシド誘導体 |
| WO2016035006A1 (en) * | 2014-09-01 | 2016-03-10 | Dr. Reddy’S Laboratories Limited | Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir |
| US20190046552A1 (en) * | 2015-04-07 | 2019-02-14 | Spring Bank Pharmaceuticals, Inc. | Compositions and methods for the treatment of hcv infection |
| MX2018014377A (es) * | 2016-05-27 | 2019-03-14 | Gilead Sciences Inc | Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3). |
| TWI860279B (zh) | 2017-09-21 | 2024-11-01 | 美商里伯賽恩斯有限責任公司 | 作為hcv rna複製抑制劑之經4'-氟-2'-甲基取代之核苷衍生物 |
-
2018
- 2018-09-21 TW TW107133372A patent/TWI860279B/zh active
- 2018-09-21 US US16/138,698 patent/US10682369B2/en active Active
- 2018-09-21 IL IL273398A patent/IL273398B2/en unknown
- 2018-09-21 CN CN201880061322.3A patent/CN111194217B/zh active Active
- 2018-09-21 EP EP18859097.0A patent/EP3684374B1/en active Active
- 2018-09-21 AR ARP180102714 patent/AR112702A1/es unknown
- 2018-09-21 WO PCT/US2018/052239 patent/WO2019060740A1/en not_active Ceased
- 2018-09-21 AU AU2018335411A patent/AU2018335411B2/en active Active
- 2018-09-21 KR KR1020207011082A patent/KR102735678B1/ko active Active
- 2018-09-21 CA CA3075645A patent/CA3075645A1/en active Pending
- 2018-09-21 SG SG11202002431SA patent/SG11202002431SA/en unknown
- 2018-09-21 JP JP2020538752A patent/JP7299897B2/ja active Active
-
2020
- 2020-05-04 US US16/865,525 patent/US11351186B2/en active Active